ProPharma has been recognized by Everest Group as a Major Contender in its Life Sciences Operations PEAK Matrix® Assessment 2023.
RALEIGH, N.C., Oct. 12, 2023 /PRNewswire-PRWeb/ -- ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, has been recognized by Everest Group as a Major Contender in its Life Sciences Operations PEAK Matrix® Assessment 2023.
The accolade follows a busy year of growth for ProPharma, including a major launch earlier this year of its Research Consulting Organization (RCO) model, which leads with strategy to de-risk programs and create tailored solutions that help organizations in the biotech, medical device, and pharmaceutical sectors, regardless of their size, confidently introduce new therapies and pursue scientific breakthroughs. Recognized by Inc. 5000 List of America's Fastest-Growing Companies, ProPharma has also leaned into AI to fasttrack the development of clinical trials and shifted to an AI-first strategy. Through a strategic partnership with H1 to optimize research and development with AI, data insights and analytics, ProPharma and H1 have co-developed ClinCHAT, an AI-powered chatbot that utilizes the latest natural language processing (NLP) and machine learning algorithms to provide a frictionless experience for users navigating complex data queries, regardless of size or development stage.
"We are honored to be named a Major Contender this year, with ProPharma making one of the biggest climbs in placement among all the companies assessed," said ProPharma Group CEO Michael Stomberg. "This achievement underscores our focus on technology-enabled consulting and delivering comprehensive solutions for our clients. In less than a year after the launch of our Research Consulting Organization model, our team has achieved a number of significant milestones and I'm immensely proud that their hard work has been recognized in this way by Everest Group."
ProPharma was evaluated by Everest Group alongside 27 other leading global life sciences operations providers based on various parameters encompassing their market adoption, portfolio mix, value delivered, vision and strategy, scope of services offered, innovation and investments, and delivery footprint. The assessment by Everest Group consisted of interactions with leading life sciences operations service providers, client reference checks, and an ongoing analysis of the life sciences operations market.
The full report can be viewed here.
About ProPharma
For over 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world's largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners' most high-profile drug and device programs. For more information about ProPharma, please visit: https://www.propharmagroup.com.
ProPharma Media Inquiries and Contacts:
Zosya Popik
Vice President, Global Marketing
ProPharma
[email protected]
Jason Wakeford
Associate Partner
Clarity for ProPharma
[email protected]
Media Contact
Jason Wakeford, Clarity for ProPharma, 424-385-4062, [email protected], https://www.propharmagroup.com/
SOURCE ProPharma
Share this article